Nymox Pharmaceutical Corporation (NYMXF)

OTCMKTS · Delayed Price · Currency is USD
0.0507
-0.0153 (-23.18%)
Mar 9, 2026, 12:00 PM EST
-56.67%
Market Cap 6.73M
Revenue (ttm) n/a
Net Income (ttm) -4.49M
Shares Out 102.04M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Average Volume 10,088
Open 0.0507
Previous Close 0.0660
Day's Range 0.0507 - 0.0507
52-Week Range 0.0322 - 0.1495
Beta 14.63
RSI 50.25
Earnings Date Mar 13, 2026

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer’s disea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1989
Employees 16
Stock Exchange OTCMKTS
Ticker Symbol NYMXF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.